Disposition of 2341 shares by Richard Pulik of Roivant Sciences at 11.84 subject to Rule 16b-3
| ROIV Stock | USD 12.48 0.23 1.81% |
Slightly above 62% of Roivant Sciences' investor base is looking to short. The analysis of the overall investor sentiment regarding Roivant Sciences suggests that many traders are alarmed. Roivant Sciences' investing sentiment can be driven by a variety of factors including economic data, Roivant Sciences' earnings reports, geopolitical events, and overall market trends.
Roivant |
Filed transaction by Roivant Sciences Officer: Cfo. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at businesswire.com
 |
Roivant Sciences Fundamental Analysis
We analyze Roivant Sciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Roivant Sciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Roivant Sciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Asset
Total Asset Comparative Analysis
Roivant Sciences is currently under evaluation in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Roivant Sciences Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Roivant Sciences stock to make a market-neutral strategy. Peer analysis of Roivant Sciences could also be used in its relative valuation, which is a method of valuing Roivant Sciences by comparing valuation metrics with similar companies.
Peers
Roivant Sciences Related Equities
| PLRX | Pliant Therapeutics | 12.39 | ||||
| LYRA | Lyra Therapeutics | 10.53 | ||||
| APLS | Apellis Pharmaceuticals | 4.39 | ||||
| INZY | Inozyme Pharma | 2.95 | ||||
| BPMC | Blueprint Medicines | 1.29 | ||||
| SNDX | Syndax Pharmaceuticals | 0.12 | ||||
| AKRO | Akero Therapeutics | 0.28 | ||||
| DAWN | Day One | 0.65 | ||||
| KRYS | Krystal Biotech | 1.27 | ||||
| PHAT | Phathom Pharmaceuticals | 1.80 | ||||
| ASND | Ascendis Pharma | 1.89 | ||||
| CGEM | Cullinan Oncology | 2.08 | ||||
| VRDN | Viridian Therapeutics | 2.55 | ||||
| BGNE | BeiGene | 4.30 | ||||
| RVMD | Revolution Medicines | 10.46 |
Additional Tools for Roivant Stock Analysis
When running Roivant Sciences' price analysis, check to measure Roivant Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Roivant Sciences is operating at the current time. Most of Roivant Sciences' value examination focuses on studying past and present price action to predict the probability of Roivant Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Roivant Sciences' price. Additionally, you may evaluate how the addition of Roivant Sciences to your portfolios can decrease your overall portfolio volatility.